Sanofi Pasteur receives further H1N1 vaccine orders

Sanofi Pasteur has received a further order for its H1N1 vaccine from the department of health and human services (HHS), it has revealed, bringing the total number it will supply up to 75.3 million doses.

This second batch is for the production of bulk antigen equivalent to 27.3 million doses based on 15 mcg of antigen per dose.

Production of the vaccine began in June, providing doses for clinical trials and in order to respond to the first order from HHS.

Wayne Pisano, president and chief executive officer of Sanofi Pasteur, said: “We recognise the important role Sanofi Pasteur serves in the country’s pandemic response plan and we have committed our resources to responding to our public health needs.”

Sanofi Pasteur made the headlines this week as it announced that a trial discovered that a prime-boost combination of the ALVAC HIV and AIDSVAX B/E vaccines lowered the rate of HIV infection by 31.2 per cent when compared with a placebo.